TerminatedPhase 2

Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)

Stopped: Due to financial restructure of SAKK

Switzerland15 participantsStarted 2019-07-25

Plain-language summary

A recent investigation showed that a substantial proportion of patients with SQCLC (46%) exhibit tumor overexpression of fibroblast growth factor receptor (FGFR) messenger ribonucleic acid (mRNA) and are potentially sensitive to FGFR-targeting treatment. Rogaratinib is a novel pan-FGFR inhibitor which showed strong anti-tumor efficacy in pre-clinical models as a single agent in FGFR pathway-addicted tumor models. SQCLC patients overexpressing tumor FGFR mRNA, who will be included into this clinical trial, do not have currently any alternative systemic treatment with a proven and clinically reasonable benefit. The objective of the trial is to determine clinical activity and safety of rogaratinib in patients with advanced SQCLC overexpressing tumor FGFR1-3 mRNA.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. without granulocyte colony-stimulating factor support within 2 weeks before the first administration of trial treatment
✓. without transfusion or erythropoietin within 2 weeks before the first administration of trial treatment

What they're measuring

Progression-free survival (PFS) at 6 months

Timeframe: at 6 months

Trial details

NCT IDNCT03762122

SponsorSwiss Cancer Institute

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-08-13

View on ClinicalTrials.gov More Squamous-cell Non-small Cell Lung Cancer trials